+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain tissues using GZMB mouse mAb with DAB staining.    

  
  

Granzyme B (GZMB) is a serine protease predominantly secreted by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It plays a critical role in inducing apoptosis in target cells during immune responses, particularly in eliminating virus-infected or cancerous cells. GZMB antibodies are essential tools for detecting and studying this protein in both research and clinical settings. These antibodies enable visualization, quantification, and functional analysis of GZMB expression across various experimental models, including flow cytometry, immunohistochemistry, and Western blotting.

In research, GZMB antibodies help investigate immune cell activity, tumor microenvironments, and autoimmune disorders where dysregulated GZMB expression may contribute to tissue damage. Clinically, they are explored as biomarkers for assessing immune response efficacy in cancer immunotherapy or chronic inflammatory conditions.

Antibodies targeting GZMB vary in specificity, with monoclonal antibodies offering high reproducibility and polyclonal antibodies providing broader epitope recognition. Validation often involves recombinant protein verification or knockout cell line controls to ensure minimal cross-reactivity. Commercial GZMB antibodies are widely available from suppliers like R&D Systems, Abcam, and BioLegend, each optimized for specific applications. Recent advancements include their use in developing therapeutic strategies, such as monitoring CAR-T cell activity or modulating immune-related adverse events. Proper validation remains crucial to avoid artifacts, given structural similarities among granzyme family members.